How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1
|
作者：
Takigawa, Nagio [1 ]
机构：
[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;
D O I：
10.1016/j.jtho.2018.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / 1440
页数：3
相关论文
共 50 条
  • [21] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [22] Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
    Watanabe, Satoshi
    Sakai, Kazuko
    Matsumoto, Naoya
    Koshio, Jun
    Ishida, Akira
    Abe, Tetsuya
    Ishikawa, Daisuke
    Tanaka, Tomohiro
    Aoki, Ami
    Kajiwara, Tomosue
    Koyama, Kenichi
    Miura, Satoru
    Goto, Yuka
    Sekiya, Tomoki
    Suzuki, Ryo
    Kushiro, Kohei
    Fujisaki, Toshiya
    Yanagimura, Naohiro
    Ohtsubo, Aya
    Shoji, Satoshi
    Nozaki, Koichiro
    Saida, Yu
    Yoshizawa, Hirohisa
    Nishio, Kazuto
    Kikuchi, Toshiaki
    CANCERS, 2023, 15 (01)
  • [23] Finding a place for ceritinib in the landscape of ALK-positive non-small cell lung cancer
    Shum, Elaine
    Gandhi, Leena
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S215 - S218
  • [24] ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
    Nensi, Shrestha
    Ashton, John
    CURRENT CANCER DRUG TARGETS, 2021, 21 (09) : 737 - 748
  • [25] Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
    Hoang, Tung
    Myung, Seung-Kwon
    Pham, Thu Thi
    Park, Boyoung
    CANCERS, 2020, 12 (03)
  • [26] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
  • [27] Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?
    Mogenet, Alice
    Tomasini, Pascale
    Greillier, Laurent
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S383 - S386
  • [28] Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China
    Guan, Haijing
    Sheng, Yanan
    Guo, Wanjie
    Han, Sheng
    Shi, Luwen
    ADVANCES IN THERAPY, 2019, 36 (05) : 1114 - 1125
  • [29] Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Zeng, Qinghua
    Zhang, Xiquan
    He, Shan
    Zhou, Zhiyong
    Xia, Luping
    Zhang, Wenxiong
    Zeng, Lin
    CHEMOTHERAPY, 2022, 67 (02) : 67 - 80
  • [30] How might treatment of ALK-positive non-small cell lung cancer change in the near future?
    Metro, Giulio
    Bellezza, Guido
    Puma, Francesco
    Chiari, Rita
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (10) : 997 - 999
12345